BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2453234)

  • 1. [Pharmacokinetics of high-dose melphalan (200 mg/m2) in a case of total renal insufficiency].
    Tranchand B; Biron P; Mercatello A; Philip T; Ardiet C
    Bull Cancer; 1988; 75(3):291-6. PubMed ID: 2453234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
    Tricot G; Alberts DS; Johnson C; Roe DJ; Dorr RT; Bracy D; Vesole DH; Jagannath S; Meyers R; Barlogie B
    Clin Cancer Res; 1996 Jun; 2(6):947-52. PubMed ID: 9816255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
    Choi KE; Ratain MJ; Williams SF; Golick JA; Beschorner JC; Fullem LJ; Bitran JD
    Cancer Res; 1989 Mar; 49(5):1318-21. PubMed ID: 2645050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation.
    Pinguet F; Martel P; Fabbro M; Petit I; Canal P; Culine S; Astre C; Bressolle F
    Anticancer Res; 1997; 17(1B):605-11. PubMed ID: 9066587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of refractory testicular cancer showing complete response to high-dose chemotherapy with autologous bone marrow transplantation].
    Ishii H; Osa Y; Okano T; Isaka S; Yasuda K; Shimazaki J; Komori I; Kodo H; Asano S
    Gan To Kagaku Ryoho; 1989 Oct; 16(10):3483-6. PubMed ID: 2478078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
    Dorr RT; Briggs A; Kintzel P; Meyers R; Chow HH; List A
    Bone Marrow Transplant; 2003 Apr; 31(8):643-9. PubMed ID: 12692603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.
    Mross K; Bewermeier P; Reifke J; Krüger W; Stockschläder M; Zander A; Hossfeld DK
    Bone Marrow Transplant; 1994 Apr; 13(4):423-30. PubMed ID: 8019466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
    Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
    Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Two cases of testicular tumors with high alpha-fetoprotein levels: a case report].
    Funahashi M; Tuchiya F; Makiyama K; Sugiura S; Miyoshi Y; Kishida T; Ogawa T; Uemura H; Yao M; Kubota Y
    Hinyokika Kiyo; 2005 Feb; 51(2):133-7. PubMed ID: 15773370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of high-dose melphalan in adults: influence of renal function.
    Kergueris MF; Milpied N; Moreau P; Harousseau JL; Larousse C
    Anticancer Res; 1994; 14(6A):2379-82. PubMed ID: 7825976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
    J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan.
    Sugarbaker PH; Stuart OA
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):151-5. PubMed ID: 17091250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
    Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Germ cell testicular tumors: understanding the kinetics of serum alpha-fetoprotein (AFP) during chemotherapy].
    Riedinger JM; Eche N; Chevreau C; Fargeot P
    Ann Biol Clin (Paris); 2008; 66(5):523-30. PubMed ID: 18957341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Case report of a non-seminomatous testicular neoplasm indicating marked efficacy of a combination chemotherapy of VBL, ACTD, BLM, CDDP and EX (VAB-4 combination therapy)].
    Hayashi M; Ebihara K; Urano E
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2775-7. PubMed ID: 6210063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.